• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

BioTime Inc.

BioTime touts preclinical results for hydrogel drug-delivery implant

December 4, 2018 By Sarah Faulkner

BioTime

BioTime Inc. (NYSE:BTX) touted today positive preclinical results for its HyStem hydrogel drug-delivery technology, demonstrating that targeted intracerebral delivery of brain-derived neurotrophic factor may alleviate the effects of ischemic brain injury and reduce neuroinflammation. The study, published in the International Journal of Molecular Sciences, focused on the effects of BDNF on sensorimotor function, infarct volume and neuroinflammation […]

Filed Under: Drug-Device Combinations, Featured, Neurological, Pharmaceuticals, Research & Development, Wall Street Beat Tagged With: BioTime Inc.

BioTime lands $1.9m grant to fund dry-AMD drug

May 29, 2018 By Sarah Faulkner

BioTime

BioTime Inc. (NYSE:BTX) said today that it won a $1.9 million grant from the Israel Innovation Authority to help support development of its dry-AMD drug, OpRegen. The company’s investigational therapy delivers retinal pigment epithelial cells into the subretinal space to replace lost RPE cells in patients with macular degeneration. BioTime is testing its drug in a […]

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: BioTime Inc.

BioTime raises $29m in public offering

October 18, 2017 By Sarah Faulkner

BioTime

BioTime Inc. (NYSE:BTX) has closed its public offering of 9,615,385 shares of common stock, the company said today, raising nearly $29 million. The Alameda, Calif.-based company said it plans to use the offering’s net proceeds to support clinical trials, R&D activities and for other general corporate purposes. In August, BioTime announced that its subsidiary, Cell Cure Neurosciences, […]

Filed Under: Featured, Funding Roundup, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: BioTime Inc.

BioTime expands OpRegen dry-AMD trial with U.S. sites

March 13, 2017 By Sarah Faulkner

BioTime

BioTime Inc. (NYSE:BTX) said today that it expanded its OpRegen Phase I/IIa trial into the U.S. with 2 new trial sites. The company’s study is evaluating its OpRegen cell therapy in patients with advanced dry form age-related macular degeneration. The 2 U.S.-based trial sites will include ophthalmologists Dr. David Boyer from the Retina-Vitreous Associates Medical Group […]

Filed Under: Clinical Trials, Featured, Optical/Ophthalmic, Stem Cells, Wall Street Beat Tagged With: BioTime Inc.

BioTime and subsidiary establish cell manufacturing facility in Israel

January 3, 2017 By Sarah Faulkner

BioTime

BioTime Inc. (NYSE:BTX) and its subsidiary Cell Cure Neurosciences said today that it is establishing an 800 square meter cell manufacturing facility at the Hadassah University Hospital in Jerusalem. The manufacturing center will be staffed initially by 30 employees, according to the companies, and will be prepared to produce OpRegen for BioTime’s ongoing clinical trial […]

Filed Under: Featured, Optical/Ophthalmic, Stem Cells, Wall Street Beat Tagged With: BioTime Inc.

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS